Search

Your search keyword '"Hivert, Bénédicte"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Hivert, Bénédicte" Remove constraint Author: "Hivert, Bénédicte" Database ScienceDirect Remove constraint Database: ScienceDirect
23 results on '"Hivert, Bénédicte"'

Search Results

3. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

4. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

5. High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia

8. Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

9. Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

11. Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

12. High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

13. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

15. Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

16. Natural history of untreated patients with type 1 Gaucher disease

17. Outcome of Patients Receiving Venetoclax for Chronic Lymphocytic Leukemia (CLL) in Real-Life Clinical Practice: Results of the French ATU Program on Behalf of the Filo Group

18. Safety Profile of Bortezomib Impacts Survival in Light Chain Amyloidosis

21. Prognostic Of IgD Myeloma In The Era Of Novel Agents

Catalog

Books, media, physical & digital resources